106 related articles for article (PubMed ID: 34321624)
21. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
23. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
24. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
25. Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway.
Sui Y; Zheng X; Zhao D
Tumour Biol; 2015 Nov; 36(11):8661-70. PubMed ID: 26044564
[TBL] [Abstract][Full Text] [Related]
26. LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression.
Xu X; Gu J; Ding X; Ge G; Zang X; Ji R; Shao M; Mao Z; Zhang Y; Zhang J; Mao F; Qian H; Xu W; Cai H; Wang F; Zhang X
Cell Death Dis; 2019 Oct; 10(10):752. PubMed ID: 31582742
[TBL] [Abstract][Full Text] [Related]
27. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
28. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
[TBL] [Abstract][Full Text] [Related]
29. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
30. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
31. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
33. Spindle and kinetochore-associated protein 2 facilitates the proliferation and invasion of hepatocellular carcinoma via the regulation of Wnt/β-catenin signaling.
Jiang J; Xu B; Zheng Y; Guo X; Chen F
Exp Cell Res; 2020 Oct; 395(1):112181. PubMed ID: 32682011
[TBL] [Abstract][Full Text] [Related]
34. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
36. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition.
Ohata T; Yokoo H; Kamiyama T; Fukai M; Aiyama T; Hatanaka Y; Hatanaka K; Wakayama K; Orimo T; Kakisaka T; Kobayashi N; Matsuno Y; Taketomi A
Cancer Med; 2017 May; 6(5):1049-1061. PubMed ID: 28374947
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.
Li Z; Tang M; Ling B; Liu S; Zheng Y; Nie C; Yuan Z; Zhou L; Guo G; Tong A; Wei Y
J Mol Med (Berl); 2014 Mar; 92(3):291-303. PubMed ID: 24281831
[TBL] [Abstract][Full Text] [Related]
39. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
Wang L; Chen C; Feng S; Tian J
Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863
[TBL] [Abstract][Full Text] [Related]
40. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway.
Zheng Y; Wang X; Wang H; Yan W; Zhang Q; Chang X
Tumour Biol; 2014 Jun; 35(6):5189-98. PubMed ID: 24573607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
